Brokerages expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) to announce $3.26 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Arcturus Therapeutics’ earnings. The lowest sales estimate is $1.00 million and the highest is $5.28 million. Arcturus Therapeutics posted sales of $2.13 million in the same quarter last year, which would indicate a positive year over year growth rate of 53.1%. The business is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Arcturus Therapeutics will report full year sales of $72.97 million for the current fiscal year, with estimates ranging from $25.00 million to $189.40 million. For the next fiscal year, analysts forecast that the business will post sales of $361.00 million, with estimates ranging from $48.07 million to $686.31 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Arcturus Therapeutics.
Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last released its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($1.47) earnings per share for the quarter, beating the consensus estimate of ($1.77) by $0.30. The firm had revenue of $5.79 million during the quarter, compared to the consensus estimate of $12.90 million. Arcturus Therapeutics had a negative return on equity of 61.88% and a negative net margin of 1,647.99%. During the same period in the previous year, the company posted ($1.25) earnings per share.
A number of hedge funds and other institutional investors have recently modified their holdings of ARCT. Bank of America Corp DE boosted its position in Arcturus Therapeutics by 26.6% in the second quarter. Bank of America Corp DE now owns 15,474 shares of the biotechnology company’s stock valued at $524,000 after buying an additional 3,248 shares during the last quarter. Invesco Ltd. boosted its position in Arcturus Therapeutics by 54.3% in the 2nd quarter. Invesco Ltd. now owns 8,754 shares of the biotechnology company’s stock worth $295,000 after purchasing an additional 3,079 shares in the last quarter. Wells Fargo & Company MN boosted its position in Arcturus Therapeutics by 9.3% in the 2nd quarter. Wells Fargo & Company MN now owns 118,218 shares of the biotechnology company’s stock worth $4,000,000 after purchasing an additional 10,086 shares in the last quarter. Morgan Stanley boosted its position in Arcturus Therapeutics by 179.6% in the 2nd quarter. Morgan Stanley now owns 247,544 shares of the biotechnology company’s stock worth $8,377,000 after purchasing an additional 159,019 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in Arcturus Therapeutics by 185.2% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 23,100 shares of the biotechnology company’s stock worth $1,080,000 after purchasing an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 76.86% of the company’s stock.
Arcturus Therapeutics stock traded down $0.50 during trading hours on Friday, reaching $26.97. The stock had a trading volume of 314,238 shares, compared to its average volume of 588,748. The company has a market cap of $711.47 million, a price-to-earnings ratio of -3.48 and a beta of 2.74. The business’s 50 day moving average price is $24.21 and its 200-day moving average price is $33.70. Arcturus Therapeutics has a 52 week low of $16.93 and a 52 week high of $65.00.
About Arcturus Therapeutics (Get Rating)
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
- The Institutional Insiders Are Buying WD-40 Company
- What’s Behind The Latest Surge In GameStop (NYSE: GME)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.